A 20-year-old woman was admitted to the hospital from the emergency department because of nausea, vomiting, and dehydration. She had no notable medical history and was taking no medications. During the previous 4 months, she had experienced intermittent nausea, vomiting, and increasing fatigue. Her symptoms had worsened during the 3 weeks before presentation, and she had sought treatment at an emergency department elsewhere 1 week before coming to our emergency department. At that time, she received intravenous hydration and was sent home with conservative treatment. She denied having abdominal pain, fever, loss of appetite, diarrhea, and headaches. However, she reported a 9-kg weight loss since her symptoms had begun. Her menstrual cycles were regular, and she denied purging behaviors, recent travel, or contact with other sick individuals. She was a nonsmoker, did not use alcohol, and denied illicit drug use. Her father had hypertrophic cardiomyopathy, but no other family members had known health problems.
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On admission, the patient was afebrile. Her supine heart rate and blood pressure were 104 beats/min and 90/60 mm Hg, respectively. While standing, her heart rate was 116 beats/min and her blood pressure was 70/50 mm Hg. She was alert, oriented, and appeared thin. Her mucous membranes were slightly dry and hyperpigmented. Examination of the neck revealed no lymphadenopathy. Heart sounds were normal, and no murmurs were detected. Lung examination yielded normal findings. Her abdomen was soft and nontender with no organomegaly. No abnormalities were identified on genital examination.
Initial laboratory tests yielded the following results (reference ranges shown parenthetically): hemoglobin, 11.1 g/dL (12.0-15.5 g/dL); mean corpuscular volume, 84.9 fL (81.6-98.3 fL); white blood cell count, 6.7 × Although acute viral gastroenteritis can account for nausea, vomiting, and dehydration, it is extremely unlikely in this patient because her symptoms had persisted for several months. In addition, both hyponatremia and hypokalemia would be expected in a patient with a history of protracted vomiting due to gastroenteritis. Patients with SIADH have hyponatremia and inappropriately elevated urine osmolality. However, SIADH can be diagnosed only if the patient is euvolemic, and our patient was hypovolemic on the basis of her orthostatic vital signs. Adrenal insufficiency most likely explains the manifestations presented in this case. Primary AI often progresses over several months and comes to medical attention when a patient becomes hemodynamically unstable. In addition, it is associated with hyponatremia, hyperkalemia, and hyperpigmentation of mucous membranes. Anorexia nervosa should always be considered in young females with recent weight loss. However, hypokalemia rather than hyperkalemia would be expected in such patients, and this disorder is not associated with hyperpigmentation of the mucous membranes. Cushing disease, or excess cortisol production, is unlikely because it is associated with hypertension, weight gain, glucose intolerance, and purple striae.
At this point in the patient's evaluation, further testing was undertaken to confirm the presumptive diagnosis. 1 Thus, random plasma cortisol measurement cannot be used to exclude AI. However, morning cortisol values below 5 µg/dL strongly suggest AI because cortisol levels are usually highest at that time. Dexamethasone suppression tests are used in cases of suspected hypercortisolism, not cortisol deficiency. The insulin tolerance test is sometimes used to diagnose secondary AI when the diagnosis is unclear, but it is not indicated in this case.
A corticotropin stimulation test was performed, and the blood samples were sent to the laboratory for analysis. While the results were pending, the patient was treated aggressively with intravenous fluid therapy. However, despite hydration, the patient continued to be hypotensive. Although the results of the corticotropin stimulation test were still pending, the patient's clinical picture strongly suggested acute AI because she continued to be hypotensive despite aggressive fluid resuscitation. Acute AI is lifethreatening, and when suspected, prompt and aggressive therapeutic interventions are necessary. Patients with AI are severely dehydrated, and aggressive fluid resuscitation with normal saline is an essential part of initial management. Mineralocorticoid replacement with fludrocortisone is not useful for emergent treatment because it takes several days for its sodium-retaining effects to become apparent. 2 Adequate sodium replacement can be achieved with use of normal saline alone. In addition, because the high doses of hydrocortisone often used to treat adrenal crisis exhibit some mineralocorticoid effects, 2 emergent administration of fludrocortisone is unnecessary. Good intravenous access is essential for providing aggressive fluid resuscitation and can be achieved with placement of 2 large-bore intravenous catheters. If a blood sample cannot be obtained in patients with suspected acute AI, dexamethasone is the preferred glucocorticoid replacement 2 because it is long acting and does not interfere with future measurements of serum cortisol levels. In patients with an established diagnosis of acute adrenal crisis, hydrocortisone (100 mg administered every 6-8 hours for the first 24 hours 2 ) can be used instead of dexamethasone. Hydrocortisone interferes with future measurements of serum cortisol levels.
The night of admission, the patient was given dexamethasone in addition to aggressive hydration, and by the next morning, her condition had improved considerably. The nausea and vomiting had ceased, and she felt less fatigued. She appeared more alert, and orthostatic hypotension was no longer evident.
Further laboratory test results were as follows: 250-µg corticotropin stimulation test, cortisol level <1 µg/dL at baseline and at 30 and 60 minutes; aldosterone, <1.0 ng/dL (1-21 ng/dL); renin activity, 18 ng/mL per hour (2.9-24.0 ng/mL per hour); and morning corticotropin, 1340 pg/mL (10-60 pg/mL). Diuretic and drug screen results were negative. The absent serum cortisol response and elevated corticotropin level were diagnostic of primary AI. 
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After AI is diagnosed, determining the cause is important for optimal management. Worldwide, infections are the most common cause of AI, and tuberculosis is often the underlying etiology. Although patients presenting initially with tuberculous AI usually have obvious active tuberculosis elsewhere, tuberculin skin testing should be performed if the etiology is unclear. 3 Abdominal CT can be helpful because abnormalities in the adrenal glands may suggest the underlying cause. These etiologies include adrenal metastases, infiltrative diseases, and adrenal hemorrhage. In our patient, fungal serologies, purified protein derivative testing, and an HIV test yielded negative results. Abdominal CT showed no adrenal abnormalities. The etiology of the patient's primary AI was presumed to be autoimmune. The patient was counseled about lifelong therapy and was instructed to take 10 mg of hydrocortisone in the morning and 5 mg in the evening. In addition, she was given a medical alert bracelet and several 1-mL syringes prefilled with dexamethasone for emergency situations. She had several questions about long-term management of this disease and asked about the safety of pregnancy.
Which one of the following statements regarding pregnancy in patients with AI is true? a. The mortality rate of pregnant women with AI is 35% to 45% b. The usual hydrocortisone dosage should be maintained throughout pregnancy, labor, and delivery c. Increased doses of hydrocortisone are usually needed only during labor and delivery d. The dosage of hydrocortisone should be doubled throughout pregnancy e. The hydrocortisone dosage should be decreased slightly during pregnancy to prevent harm to the fetus
Before glucocorticoid replacement therapy became available, pregnancy in women with primary AI was associated with a maternal mortality rate as high as 35% to 45%. 4 Currently, patients with AI who receive appropriate treatment and antenatal care have no risk of death during pregnancy. During pregnancy, these women should continue their usual dosages of medication, but during labor and delivery, higher doses are often needed because of the associated biological stress. During labor, patients should be treated with adequate saline hydration and should double their daily hydrocortisone dosage. With prolonged labor and during delivery, 50 mg of hydrocortisone should be administered. 5 In women undergoing cesarean section, 100 mg of hydrocortisone should be administered every 6 hours. 5 Soon after delivery, the dosage can be tapered rapidly, and the patient can often use her routine maintenance dosage within 3 days after delivery. Although during a normal pregnancy the maternal plasma concentration of cortisol increases between gestational week 12 and term to reach levels 3 to 5 times the prepregnancy level, increased corticosteroid dosages are rarely needed during pregnancy in women with AI. 4 The patient's maintenance dosage should not be decreased because inadequate treatment of AI during pregnancy is associated with maternal morbidity and mortality and fetal growth retardation. 5 At follow-up a few weeks after diagnosis and initial management, the patient continued to take 10 mg of hydrocortisone in the morning and 5 mg at night. She was feeling well, and her symptoms had completely resolved.
DISCUSSION
Adrenal insufficiency is characterized by the impaired ability of the adrenal cortex to produce cortisol in response to normal physiologic demands. Primary AI is caused by destruction of the adrenal gland or disruption of cortisol synthesis. Secondary AI occurs when there is diminished corticotropin secretion from the pituitary gland, resulting in lack of stimulation of the adrenal gland. Although the primary defect in patients with secondary AI is not in the adrenal gland, the zona fasciculata will eventually atrophy from decreased stimulation.
Certain clinical features can help distinguish primary from secondary AI. In primary AI, corticotropin levels are high and can cause hyperpigmentation, especially on the elbows, knees, and buccal mucosa. In secondary AI, corticotropin levels are either low or inappropriately within the normal range, and hyperpigmentation is not present. In addition, the aldosterone deficiency present in primary AI leads to hypovolemia, orthostatic hypotension, and hyperkalemia. These fluid and electrolyte abnormalities are less likely in secondary AI because aldosterone secretion is intact. 1 Our patient was seen by several physicians before AI was diagnosed. This is a common scenario for many patients with chronic AI because the symptoms of chronic fatigue, depression, weakness, anorexia, and nausea are extremely nonspecific, and classic symptoms such as hyperpigmentation are not always present. In fact, AI is diagnosed in many patients only when they experience an adrenal crisis. 6 Autoimmune destruction of the adrenal gland or Addison disease, the most common cause of primary AI, occurs slowly over months to years, which makes the diagnosis difficult to establish.
1 By the time the patient has a low serum cortisol concentration, adrenal destruction is nearly complete. 6 Adrenal insufficiency should be considered in all patients with any of the aforementioned nonspecific symptoms. In addition, if adrenal crisis is suspected, treatment must be initiated immediately. Short-term treatment is usually not harmful if the diagnosis is incorrect, but delaying treatment in a patient who has AI can be life-threatening. When the patient's condition has stabilized, the diagnosis should be confirmed with definitive tests. Measurement of morning serum cortisol levels and the corticotropin level can be the initial tests in ambulatory patients. 6 However, the morning cortisol concentration is often in the low-normal range, which is not helpful in excluding AI. 6 Corticotropin stimulation testing is easy and has the sensitivity and specificity to diagnose AI in the vast majority of patients.
Determining the underlying etiology of AI is important because it may affect future patient management. The most common cause of primary AI in developed countries is autoimmune adrenalitis, accounting for 70% of the cases. 7 Other autoimmune diseases such as hypothyroidism, pernicious anemia, and type 1 diabetes mellitus are often associated with primary AI. In developing countries, infectious causes are most common, especially tuberculosis. Of importance, medications can also affect adrenal function. 7 Medication use could be the primary etiology or could contribute to the dysfunction of an already failing gland. For example, a patient with histoplasmosis may have subclinical adrenal disease that worsens in response to ketoconazole, which inhibits the cytochrome P-450 system needed for cortisol metabolism. Discontinuation of longterm exogenous glucocorticoid therapy is the most common cause of secondary AI. Other causes of primary AI include hemorrhage into the adrenal gland, metastases, and infiltrative diseases. Adrenoleukodystrophy, congenital adrenal hypoplasia, and familial glucocorticoid deficiency are extremely rare causes of primary AI. 1 Chronic AI necessitates lifelong daily corticosteroid replacement. The goal is to provide glucocorticoid doses that mimic the normal cortisol secretion pattern. The lowest effective dosage is recommended. Traditionally, dosages of 25 to 30 mg/d were prescribed, but these regimens were often associated with decreased bone density. 8 Recent studies have shown that divided dosages of 15 to 25 mg/d are adequate and less likely to be associated with decreased bone density. 9 A larger dose is often taken in the morning and a smaller dose in the afternoon. The second dose is usually taken between 4 and 5 PM to mimic diurnal variation and to lower the incidence of insomnia, an occasional adverse effect of glucocorticoid therapy. 9 General clinical signs, such as a good appetite and sense of well-being, are guides to the adequacy of the replacement therapy. 9 Obviously, signs of Cushing syndrome indicate overtreatment.
Often, patients with primary AI also require mineralocorticoid replacement in the form of fludrocortisone. The dosages needed usually range from 0.05 to 0.2 mg/d. 4 Because of the long half-life of this agent, divided doses are not required. About 10% of patients with primary AI do not require mineralocorticoid therapy. 4 Electrolyte, plasma renin activity, and blood pressure measurements are used to assess the adequacy of mineralocorticoid therapy. 9 Increasing evidence suggests that female patients with AI may have improved sexual function and well-being with 25 to 50 mg/d of dehydroepiandrosterone (DHEA). In a randomized double-blind trial of 39 patients with Addison disease, Hunt et al 10 found that 50 mg/d of oral DHEA improved self-esteem, mood, fatigue, and overall wellbeing. However, results from other studies are inconsistent, and currently, treating AI patients with DHEA is not considered standard care.
"Stress dosing" (administering higher doses of corticosteroid during periods of biological stress) is recommended for patients with chronic AI and for those taking long-term glucocorticoid therapy. Unfortunately, prospective studies regarding stress dosing, especially in patients with primary AI, are lacking. Perioperative corticosteroid coverage can be managed in several ways. Generally, hydrocortisone dosages are increased to 200 to 300 mg/d for patients undergoing surgical procedures. 7 Patient education about AI is important. Adherence to daily therapy should be emphasized, as well as the need for dose adjustments during stressful situations. All patients should be advised to wear a medical alert bracelet and to carry dexamethasone-prefilled syringes for emergencies in which the patient cannot take medication orally.
Before therapy became available, primary AI was often fatal, and death usually occurred within 2 years of disease onset. Currently, survival depends on the underlying cause of the disease. Patients with autoimmune primary AI can live normal lives and have a life expectancy similar to that of the general population. Deaths due to AI usually occur only in patients with rapid onset of disease who may die before the diagnosis is established and appropriate therapy initiated.
